CURRENT TRIALS

SPONSOR: ALTO NEUROSCIENCE INC-

INDICATION: MAJOR DEPRESSIVE DISORDER

STUDY: ALTO-300-201: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

LOCATION: GEORGIA

SPONSOR: SHIONOGI

INDICATION: SYMPTOMATIC SARS-CoV-2

STUDY: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF S-217622 IN THE PREVENTION OF SYMPTOMATIC SARS-CoV-2 INFECTION IN HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19 

LOCATION: FLORIDA